Wu et al. carried out an in vivo study using anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC) models in combination with chemotherapeutics as neoadjuvant (preoperative) therapies for resectable TNBC. Here, CD274 is linked to renal cell carcinoma.